STERIS Announces Financial Results for Fiscal 2027 First Quarter

* Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% * Fiscal 2027 first quarter as reported diluted EPS increased to $2.04; adjusted EPS per diluted share increased to $2.59 * Targeted restructuring plan announced associated with new Formulated Chemistries Center of Excellence in North Carolina DUBLIN, IRELAND, Aug. 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 first quarter ended June 30, 2026. Total revenue for the first quarter of fiscal 2027 increased 7% to $1.5 billion compared with $1.4 billion in the first quarter of fiscal 2026. Constant currency organic revenue growth was 6% in the first quarter.

“We are pleased with our performance in the first quarter,” said Dan Carestio, President and CEO of STERIS. “Our first quarter results reflected stable underlying demand, while our commercial teams continue to drive meaningful growth within the Healthcare segment. In particular, share gains in consumables and services are fueling our performance, underpinned by solid order growth for capital equipment. Our revenue and earnings expectations for the year are unchanged, as the strength of our portfolio continues to enable us to help our Customers navigate a complex operating environment.”